Stock POLYMED POLY MEDICURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Poly Medicure Limited

Equities

POLYMED

INE205C01021

Market Closed - Bombay S.E.
Other stock markets
 06:00:48 2024-04-29 am EDT 		5-day change 1st Jan Change
1,640 INR +0.39% Intraday chart for Poly Medicure Limited +5.90% +9.99%
Feb. 02 Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024
Jan. 31 Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 61.64 times its estimated earnings per share for the ongoing year.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
POLY MEDICURE LIMITED Stock Poly Medicure Limited
+9.99% 1.88B
C
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.54% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.85% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.26% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.39% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.82% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+6.01% 40.84B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.49% 26.48B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.65% 26.25B
A-
TERUMO CORPORATION Stock Terumo Corporation
+17.74% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. POLYMED Stock
  4. Ratings Poly Medicure Limited